SPC2996 is a novel locked nucleic acid phosphorothioate antisense molecule targeting the mRNA of the Bcl-2 oncoprotein. We investigated the mechanism of action of SPC2996 and the basis for its clinically observed immunostimulatory effects in chronic lymphocytic leukemia (CLL). Patients with relapsed CLL were treated with a maximum of six doses of SPC2996 (0.2-6 mg/kg) in a multicenter phase I trial. Microarraybased transcriptional profiling of circulating CLL cells was carried out before and after the first infusion of SPC2996 in 18 patients. Statistically significant transcriptomic changes were observed at doses X4 mg/kg and occurred as early as 24 h after the first infusion of the oligonucleotide. SPC2996 induced the upregulation of 466 genes including a large number of immune response and apoptotic regulator molecules, which were enriched for Toll-like receptor response genes. Serum measurements confirmed the release of pro-inflammatory cytokines including chemokine (C-C motif) ligand 3 (macrophage inflammatory protein 1a) and tumor necrosis factor-a, thereby validating the in vivo transcriptomic data at the protein level. SPC2996 caused a X50% reduction of circulating lymphocytes in five of 18 (28%) patients, which was found to be independent of its immunostimulatory and anti-Bcl-2 effects.
Introduction
B-cell chronic lymphocytic leukemia is the most prevalent leukemia in Europe and the United States and is characterized by the accumulation of CD5 þ CD23 þ CD19 þ clonal B cells. 1 At the molecular level, leukemic cell expansion in the patient is currently thought to be mainly due to a defect in the apoptotic machinery, which results at least in part from the aberrant overexpression of the antiapoptotic Bcl-2 oncoprotein in the leukemic cells. 2 Overexpression of Bcl-2 protein also plays an important role in chemotherapy resistance, aggressive clinical course and adverse survival in CLL patients. 3 On the basis of these observations, several clinical trials have been initiated to explore the role of Bcl-2 antisense therapy in CLL and other lymphoproliferative disorders. [4] [5] [6] [7] The antisense phosphorothioate oligonucleotide oblimersen is complementary to the first six codons of the open reading frame of the human Bcl-2 mRNA sequence and has been shown to downmodulate the Bcl-2 protein in pre-clinical studies using human cell lines of B-cell origin. 8 Clinically, oblimersen displayed modest single-agent activity in a phase I/II trial in heavily pretreated patients with CLL. 7 More importantly, oblimersen appears to potentiate the cytotoxic activity of agents commonly used in CLL. 9 This was shown by a recently updated randomized phase III trial in relapsed/refractory CLL showing an overall survival advantage for patients treated with the combination of oblimersen with fludarabine and cyclophosphamide in comparison to the control group treated with fludarabine and cyclophosphamide alone. 5, 6 Although the clinical efficacy of oblimersen combination therapy has been proven in this study, it is not clear as to whether its beneficial effect results from the downregulation of Bcl-2 in the leukemic cells and/or other non-antisense effects, including pro-inflammatory and immunomodulating actions. 8, 10 We have recently performed a phase I/II study in patients with relapsed/refractory CLL using the novel antisense oligonucleotide SPC2996 (ClinicalTrials.gov Identifier: NCT00285103). SPC2996 is a representative of a new class of antisense reagents. It is an oligonucleotide comprising 16 monomeric units (16-mer) , of which four DNA nucleotides are replaced with locked nucleic acid nucleotides. 11 Although SPC2996 differs in only three nucleotides from the oblimersen sequence, the incorporation of novel locked nucleic acid into the molecule may offer several advantages over the traditional phosphorothioate oligonucleotides, including increased target sequence affinity, specificity, higher biostability and reduced immunostimulatory side effects. 10, 12 Pre-clinically SPC2996 was recently shown to be efficiently incorporated into several different tumor cell types and specifically downregulate the Bcl-2 protein in these cells. 13 We report here the results of a translational research companion study employing microarray-based transcriptomic profiling and serum protein analyses to investigate the in vivo mechanism of action of SPC2996 in CLL patients.
Methods
Patients, study design and treatment CLL patients treated with the Bcl-2 antagonist SPC2996 were enrolled on the institutional review board-approved SPC-101 study (ClinicalTrials.gov Identifier: NCT00285103). The clinical results and toxicity data of this phase I study (N ¼ 35) will be described in a separate report (Coiffier et al., manuscript in preparation). Patient selection for this study was based on the availability of RNA samples isolated from the peripheral blood (PB) of study patients (N ¼ 18). The patients' baseline characteristics are given in Table 1 . Eligible patients were assigned sequentially through cohorts A to E and received SPC2996 at 0.2, 0.5, 1.0, 2.0 and 4.0 mg/kg for six doses within 12 days (days 0, 2, 5, 7, 9 and 12); in cohorts F and G, patients received SPC2996 at 4.0 and 6.0 mg/kg for three doses at days 0, 3 and 7 (Table 1 ). SPC2996 was dissolved in 100 ml saline and intravenous infusions were given during a 2-h period, unless infusion reaction necessitated a rate reduction. Allopurinol 300 mg was given for 14 days in cohorts E, F and G starting the day before the first infusion of SPC2996.
Clinical samples and RNA purification
In all, 57 samples were available from 18 patients. Supplementary Table S1 gives a detailed overview of the patients' sample characteristics. Whole PB samples were collected at the designated time points (Supplementary Table S1 ) and stored at À80 1C for up to 3 years using the PAXgene blood stabilizing system (Qiagen, Hilden, Germany) according to the recommendations of the manufacturer. RNA was extracted after thawing the frozen PAXgene tubes employing the Qiagen PAXgene extraction kit (Qiagen) and subsequently purified using the RNeasy MinElute Cleanup Kit (Qiagen). The quality of total RNA prepared from frozen PAXGene tubes was assessed using standard UV spectrophotometry and by examining electropherogram images generated with the Agilent Bioanalyzer.
Gene expression profiling
Gene expression profiling (GEP) was performed using 5 mg of total RNA with an Affymetrix GeneChip Human Genome U133 Plus 2.0 Array, which contained more than 54 000 probe sets for the analysis of about 47 000 transcripts (Affymetrix, High Wycombe, UK). Amplification, hybridization and scanning were all carried out according to standard Affymetrix protocols (GeneChip Expression Analysis Technical Manual_v2) as described recently.
14 The raw experimental data can be accessed through the internet (http://www.ncbi.nlm.nih.gov/ geo/). The methods of microarray data analysis are outlined in Supplementary Materials.
Measurement of serum cytokines and immunoglobulin levels
Serum samples obtained from study subjects before treatment and at different time points following the first infusion of SPC2996 were stored at À80 1C. The cytokines and chemokines interleukin (IL)-2, IL-4, IL-6, IL-8, IL-10, interferon (IFN)-g, IFN-a, MCP-1 (chemokine (C-C motif) ligand 2 (CCL2)), macrophage inflammatory protein 1a (MIP-1a) (CCL3) and tumor necrosis factor-a (TNF-a) were measured using Fluorokine MultiAnalyte Profiling (F-MAP) kits from R&D Systems (Minneapolis, MN, USA) on a Luminex IS100 instrument (Luminex Corp., Austin, TX, USA). Total immunoglobulin M (IgM) serum levels were measured by enzyme-linked immunosorbent assay as part of the safety evaluation at the study's central laborator's laboratory (Charles River Laboratories, Edinburgh, UK).
Effects of SPC2996 on CLL cells in vitro
Peripheral blood mononuclear cells were isolated using Lymphoprep (Invitrogen, Karlsruhe, Germany) density gradient centrifugation from seven untreated patients with CLL seen at our institution after obtaining informed consent. Peripheral blood mononuclear cell with a CLL cell purity 480% as detected by fluorescence-activated cell sorting determination of CD19 þ CD5 þ cells were cultured at a concentration of 1.5 Â 10 6 /ml in stroma cell conditioned medium (prepared from the human stromal cell line HS5 15 ) in the presence or absence of the designated ODN. A list of the oligonucleotides employed in this study is presented in Supplementary Table S2. After 2 days incubation in a 5% CO 2 and air incubator at 37 1C, cell culture supernatants were frozen at À80 1C until cytokine analysis using the Luminex platform.
Statistical analysis
Unless otherwise indicated, comparison of parameters between subgroups was performed using the non-parametric MannWhitney U-test or Kruskal-Wallis test for continuous variables. A P-value o0.05 was regarded significant. All bar graphs represent mean±standard deviation.
Results

Patient characteristics and isolation of RNA for GEP
In all 57 samples collected at the designated time points from 18 patients (range 2-4 samples per patient) assigned to the Table S1 ). The quality of total RNA prepared from frozen PAXGene tubes was assessed using standard UV spectrophotometry and by examining electropherogram images generated with the Agilent Bioanalyzer. Supplementary Table S3 gives a summary of the quality control data and array performance metrics. RNA was of high quality as evidenced by an average RNA integrity number score of 8.2±0.52 (mean ± s.d.) and sufficient quantity (25.9 ± 20.5 mg, range 3.8-98.1 mg) for microarray analysis in 57/57 (100%) samples (Supplementary Table S3 ). cRNA synthesis suitable for subsequent microarray analysis was successful in all samples (57/57, 100%); however, in one case (401-3), the array hybridization failed, resulting in a damaged array image (Supplementary Table  S3 ). Owing to a lack of sufficient quantity of remaining RNA of this particular sample, the hybridization procedure could not be repeated. In aggregate, technically robust and informative microarray analyses could be performed in 56/57 (98.2%) samples.
Pharmacological effects of SPC2996 in this patient cohort
None of the patients in this study achieved a durable clinical response (PR or CR) after treatment with SPC2996 using the 1996 NCI criteria. 16 Changes in circulating lymphocyte numbers (reflective of tumor burden) during the trial are shown in Supplementary Figure S1 . Overall, SPC2996 induced a dosedependent reduction in circulating CLL cells 450% in 5/18 (27.8%) cases (Table 2 ), which usually closely followed the first infusion of SPC2996 within hours to days (Supplementary Figure S1 ). CD19 þ CD5 þ CLL cells represented more than 80% of the circulating lymphocytes in these patients. However, we were interested to investigate whether SPC2996 induced a selective clearance of leukemic cells or whether it also affected the number of non-leukemic lymphocytes, that is, accessory T and NK cells. Flow cytometry data allowing for the enumeration of lymphocyte subsets were available in four of the five patients showing a 450% reduction in PB lymphocytes in response to SPC2996 treatment. Supplementary Figure S2 shows that therapy with SPC2996 led to a concordant reduction of all lymphocyte subpopulations, that is, CD19 þ CD5 þ CLL along with non-leukemic T and NK cells.
Furthermore, we also observed clinical evidence of an inflammatory reaction as defined by pyrexia and/or painful lymphadenopathy, which was caused by SPC2996 in 7/18 cases (38.9%; Table 2 ). Although inflammatory reactions were also predominantly observed in patients receiving higher doses of the oligonucleotide (42 mg/kg), there was no statistically significant correlation between a 450% reduction of circulating CLL cells and occurrence of either pyrexia or lymphadenopathy (P40.05) after first dosing of SPC2996.
Pharmacodynamic effects of SPC2996 on the gene expression profile of CLL cells in vivo
Changes in the transcriptomes of CLL cells in response to different doses of SPC2996 were analyzed using the Affymetrix HG U133 Plus 2.0 microarray platform following the evaluation strategy outlined in Supplementary Figures S3 and S4.
Unsupervised cluster analysis
An initial exploration of the data set was performed employing a hierarchical unsupervised clustering algorithm ( Figure 1) showing that most of the genes represented on the microarray were not altered in expression by SPC2996 treatment. In general, the 2-4 expression profiles obtained from individual patients formed separate subclusters, that is, showed highest similarity, whereas the profiles of individual patients were clearly separated. However, one mixed subcluster composed of three samples of the high-dose group (452-24 h, 404-24 h and 443-24 h) and the two samples from patient 441 was observed, which all exhibited overexpression of a high number of immune response genes (Cluster 1; Supplementary Table S4 ). Two of these latter patients (404 and 443; Figure 1 ) also exhibited clinical features of an inflammatory response in vivo (Table 2) . Interestingly, overexpression of immune response genes in these patient clusters coincided with the downregulation of genes (Cluster 2; Supplementary Table S4), which were enriched for metabolic and ribosomal genes on pathway analysis and also included the SPC2996 target Bcl-2.
Supervised paired analysis using 'significance analysis of microarrays'
As the biological effects including reduction in the number of circulating CLL cells and pro-inflammatory reactions were clearly dose-dependent and mostly observed in patients receiving SPC2996 at doses exceeding 2 mg/kg (that is, 4-6 mg/kg designated 'high-dose group', N ¼ 11; Table 2 ), paired significance analysis of microarrays were performed separately for patients assigned to p2 mg/kg SPC2996 ('low-dose group', N ¼ 7) and patients receiving 4-6 mg/kg SPC2996. At the 4 h and 4-week time points after the first infusion of SPC2996 (Supplementary Figure S3) , no statistically significant changes in gene expression could be observed in neither of the two patient groups. By contrast, comparing pretreatment samples with the 24 h post-first treatment time point identified 466 statistically highly differentially expressed genes (DEG, 'SPC2996 response genes'; Supplementary Table S5) in the 'high-dose patient group' (N ¼ 11), whereas no changes in the transcriptomes of 'low-dose patients' (N ¼ 7) could be detected. Table 2 Pharmacological effects of SPC2996 in this patient cohort
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Functional pathway analysis of SPC2996 response genes
To further investigate specific molecular pathways that may be altered in response to SPC2996 in CLL cells, the 466 DEG identified by significance analysis of microarrays of the pretreatment vs 24 h post-first treatment samples in the 'highdose' patient subgroup (Supplementary Table S5 ) were subjected to functional pathway analysis using the Genetrail software package (http://genetrail.bioinf.uni-sb.de/index.php). Using a P-value of 0.05 and the KEGG (Supplementary Table  S6A ) and Gene Ontology (Supplementary Table S6B ) databases as a read out, we found that the 466 DEG are highly enriched for genes that play an important role in a wide range of biological processes, most of which involve cell activation and regulation of immune response. In view of the observed pro-inflammatory effects of SPC2996 and data available from the literature on the effects of oblimersen and other therapeutic oligonucleotides, 7,10,17 we selected genes comprised in the following biologically relevant pathways/categories for further detailed analysis: Toll-like receptor (TLR) signaling, apoptosis and immune response (Supplementary Table S6 and Figure 2) . Importantly, all of the DEG comprised in these three functional categories were found to be upregulated in response to SPC2996 treatment as indicated by the red color in the heat map. This finding in combination with the absence of a statistically significant regulation of these genes in the 'low-dose group' (as indicated by the black and green color; Figure 2) suggests that SPC2996 exerted a strong dose-dependent stimulatory effect on the CLL cells, which represent the majority of the cells in the PB. Importantly, genes found to be upregulated in the Gene Ontology category 'apoptosis' (Figure 2 ) included both pro-apoptotic (for example, ZAK, TNF, TP63, MMP9, MAPK1, BCL3, BCL6, BNIP3L, BID, TLR2, GPX1, PPP3R1, DRAM) and antiapoptotic genes (NFKB1, BAG1, TNFSF13B, PIM1, IL1B). In line with the quantitative PCR results (data not shown) generated in the same samples, we could not detect a consistent effect of SPC2996 on Bcl-2 transcript levels in CLL cells at the 24-h time point (Figure 2) .
Using a similar evaluation strategy, we also plotted gene expression profiles that were sequentially obtained in individual patients (Figure 2 ). Although GEP results at the 4-h time point failed to reach statistical significance when applying stringent significance analysis of microarray statistical criteria to the complete data set, this analysis revealed a clear upregulation of the TLR early response genes TNFa (patients 404, 428 and 452), CCL3 (MIP-1a, patients 404, 428, 448 and 452) and IL8 (patients 404 and 428) in individual patients. Of note, transcript levels of SPC2996 response genes returned to pretreatment values within the 4-week observation period after the first infusion (Figure 2 ), suggesting that these stimulatory effects of the oligonucleotide are reversible.
Validation of microarray studies using Luminex protein analysis of patient serum samples
In 15/18 cases subjected to GEP serum, samples were available for proteomic analysis using the Luminex platform (Supplementary Table S1 ). SPC2996 did not cause statistically significant Figure 1 Unsupervised hierarchical cluster analysis of all samples subjected to expression array analysis (n ¼ 56). Red areas indicate increased expression, and green areas indicate decreased expression. Each column represents a single CLL sample isolated from one of N ¼ 18 CLL patients (Tables 1 and 2 ) at different time points before or after the infusion of SPC2996. The sample identification code is given at the bottom of the graph and corresponds to the identification code shown in Table 1 CD14  IL1B  IL8  MAP2K3  NFKB1  NFKB2  NFKBIA  TLR5  TNF   AP2B1  AP2M1  AQP9  BCL3  BCL6  BNIP3L  C5AR1  CCL3  CCR1  CD14  CD276  CD83  CFP  CLEC4A  CLEC4D  CLEC4D  CR1  ECSIT  FCAR  FCER1G  FCER1G  IL1B  IL1RN  IL1RN  IL8  KRT1  MARCH8  NFKB2  RELB  TLR2  TLR5  TNF  TNFSF13B   BCL6  BID   BID  BNIP3L  C11orf82  CARD6  CD14  CTSB  CTSB  CTSB  DRAM  FCER1G  FCER1G  FKBP8  GADD45B  GADD45B  GPX1  GSPT1  GSPT1  IL1B  MAPK1  MMP9  NFKB1  NFKBIA  PIM1  PPP3R1 /// WDR92  PRDX2  RTN3  SGPL1  SNCA  SNCA  SOD2  SOD2  TCF7L2  TCF7L2  TCF7L2  TLR2  TNF  TNFAIP3   TP63   TNFSF13B   TSPP  ZAK   BID   404_4h  428_4h  448_4h  449_4h  450_4h  451_4h  452_4h  401_24h  402_24h  403_24h  411_24h  422_24h  424_24h  427_24h  404_24h  425_24h  428_24h  443_24h  444_24h  449_24h  450_24h  441_24h  448_24h  451_24h  452_24h  402_4w  403_4w  411_4w  422_4w  424_4w  427_4w  425_4w  428_4w  443_4w  449_4w  450_4w  451_4w Table S5 ) and its target Bcl-2 (separate panel at the bottom of the graph). Colored horizontal lines above the graph indicate the dose of SPC2996 applied to the respective patient. Note that at the 24-h time point, SPC2996 induced some downmodulation of Bcl-2 expression in CLL cells from patients treated in the high-dose group (X4 mg/kg) as compared with the low-dose cohort (p2 mg/kg). However, these differences did not reach statistical significance (P40.05). For further details see legend to Figure 1 and Supplementary methods.
Pharmacodynamic effects of SPC2996 in CLL patients J Dürig et al changes in the serum levels of IL-2, IL-4, IL-6, IL-10, IFN-g and IFN-a. By contrast, we observed statistically significant increases of CCL3 (MIP-1a), TNF-a and CCL2 (MCP-1) serum levels ( Figure 3 ) compatible with a pro-inflammatory cytokine release in response to SPC2996. Changes in serum protein concentration as detected by enzyme-linked immunosorbent assay nicely correlated with the GEP data shown in Figure 2 , in which CCL3 and TNF-a were also found to be strongly upregulated in response to SPC2996. In contrast, we observed discordant results for the TLR9-inducible chemokine CCL2 (MCP-1), 18 which was found to be upmodulated at the protein level, but not by GEP (Supplementary Table S5 ). This discrepancy may be technical in nature and explained by the small number of patients included in this analysis. An alternative explanation may be that CCL2 is secreted by cells other than CLL cells (for example, monocytes/macrophages), which account for less than 5% of the circulating white blood cells, and thus are under-represented in the RNA samples used for GEP.
Effects of SPC2996 on IgM serum levels in vivo
CpG containing oligonucleotides have recently been shown to induce the differentiation of memory B cells into plasma cells, 19 which may be indirectly mediated at least in part by the increased production and secretion of B-cell-activating factor of the TNF family (BAFF, TNFSF13B). 20 As a result of this process, CpG-stimulated memory B cells were found to secrete increased levels of low-affinity IgM. 21 In view of the facts that (i) most experts in the field now consider CLL cells as the malignant counterparts of antigen experienced memory B cells, (ii) BAFF (TNFSF13B) was found to be strongly upregulated in response to SPC2996 (Figure 2 and Supplementary Table S5 ) and (iii) results of the functional pathway analysis suggested stimulation of 'TLR signaling' and 'Ig production' (Supplementary Table S6B), we hypothesized that SPC2996 induce the production of antibodies that may reflect plasmacytic differentiation of CLL cells in vivo.
To further address this possibility, we serially measured IgM serum levels in patients before and after treatment with SPC2996. Indeed, during the observation period of 4 weeks following the first infusion of SPC2996, we found increases in IgM serum concentrations X50 and X100% over pretreatment values in 8/15 and 5/15 of the patients, respectively. Furthermore, there was a clear trend towards a concentrationdependent effect in that increases in IgM serum levels were generally more pronounced in patients receiving X4 mg/kg of the study compound (Figure 4) . However, our serum IgM measurements did not allow determining the source of the antibodies, which could be derived from both CLL and/or normal memory B cells (see Discussion). Supplementary Table S5 were analyzed for the following cytokines and chemokines: CCL2, CCL3, IL-8 and TNF-a using the Luminex platform as described in Methods. Statistical comparisons of experimental groups with the pre-infusion samples were performed using the Wilcoxon test for paired samples. *Po0.05.
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Effects of SPC2996 on cytokine production by CLL cells in vitro
To further confirm that the pro-inflammatory effect of SPC2996 results from direct stimulation of CLL cells, we performed in vitro studies where CLL cells were exposed to different concentrations of SPC2996 and control oligonucleotides. We determined the concentration of CCL3 and TNF-a in the cell culture supernatants and found that the leukemic cells proved capable of secreting both of these cytokines exhibiting a dosedependent response to SPC2996 stimulation ( Figure 5 ). For comparison, we determined the effect of the TLR9 agonistic CpG ODN2216 and a control ODN SPC4077 on the same samples. ODN2216 was more potent in inducing the secretion of both CCL3 and TNF-a by CLL cells than SPC2996, whereas SPC4077 did not show an effect under these experimental conditions. These latter results together with the microarray studies provide circumstantial evidence that the CLL cells are indeed the probable source of the increased CCL3 and TNF-a serum levels observed after SPC2996 infusion in the patients.
Discussion
In this study, we employed microarray-based GEP in combination with serum protein analysis to investigate the pharmacodynamic effects exerted by the novel locked nucleic acid antisense Bcl-2 inhibitor SPC2996 on CLL cells in vivo. Transcriptional profiling has recently been increasingly used in the context of early phase I oncology trials to identify biomarkers that may help predict the clinical outcomes of novel targeted treatment modalities in cancer patients. 22, 23 However, because of their greater accessibility, expression profiles are often generated from surrogate tissues, such as peripheral blood mononuclear cells and not from the tumor itself, which is an obvious limitation of this approach. 22 By contrast, CLL may be a disease entity ideally suited for transcriptomic studies as the tumor cells can be easily collected from the PB and directly analyzed for gene expression changes induced by novel therapeutic agents. Although PB is a potentially valuable source of transcriptomal information, the 
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J Dürig et al literature on microarray-based pharmacogenomic in vivo studies in CLL is scarce. 24 This may be due to the high costs involved and more importantly problems with the logistics of sample acquisition, storage and subsequent preparation of highquality RNA sufficient for microarray analysis. In this context, it is worth noting that we were able to obtain technically robust and informative microarray analyses from a single 2.5 ml blood sample in 56/57 (98.2%) cases. These results expand recent studies showing that extraction of microarray-grade RNA from frozen whole blood stabilized in PAXGene tubes is technically feasible 23, 25 to the setting of a European multicenter phase I trial including non-academic study sites.
There were two important clinical observations in this study that we aimed to further investigate by our microarray analysis. First, we found that SPC2996 induced a dose-dependent reduction in circulating CLL cells by more than 50% in about one-third of the patients. However, clearance of leukemic cells that usually closely followed the first infusion of SPC2996 within hours to days did not translate into durable clinical remissions. Second, we observed clinical evidence of an inflammatory reaction as defined by pyrexia and/or painful lymphadenopathy, which was caused by SPC2996 in 39% of the patients in a dosedependent manner.
Transcriptomic profiling of PB samples provided an explanation for the inflammatory reaction to SPC2996 observed in the study patients. Comparing pretreatment samples with the 24 h post-first treatment time point in a supervised bioinformatic analysis identified a panel of 466 statistically highly differentially expressed genes, all of which were found to be upregulated in response to SPC2996. Further functional statistical analysis revealed that these SPC2996 response genes were highly enriched for genes that play important roles in cell activation and regulation of immune responses. Of particular interest, SPC2996 was found to induce the production of a plethora of pro-inflammatory effector molecules, including IL-1b, MIP-1a and TNF-a through the TLR signaling pathway, which plays a central role in innate immunity. Serum measurements confirmed the release of pro-inflammatory cytokines and chemokines including MIP-1a and TNF-a, thereby validating the in vivo transcriptomic data at the protein level.
Taken together, these findings are reminiscent of recent studies reporting inflammatory side effects in CLL patients treated with oblimersen. 3, 7 The antisense Bcl-2 oblimersen is an 18-mer phosphorothioate oligonucleotide, which differs in only three nucleotides from the 16-mer SPC2996. 3 Its clinical use in CLL has been complicated by unexpected toxicities involving tumor flare and inflammatory reactions as part of a cytokine release syndrome, the etiology of which is not well understood. Pre-clinical studies by Jahrsdö rfer et al. 17, 26, 27 and others 10, 28 suggest that oblimersen exerts non-antisense effects on CLL cells that are likely mediated by the TLR signaling pathway. It has been hypothesized that after incorporation into the CLL cell, CpG motifs present in the nucleotide sequence of oblimersen (and also SPC2996) activate TLR9, which is abundantly expressed in CLL. 3, 29, 30 Our microarray data strongly support this concept and expand it to the in vivo situation. To confirm that the CLL cells are the source of the pro-inflammatory cytokines released into the serum, we performed in vitro studies where CLL cells were cultured in the presence of SPC2996 or control oligonucleotides. Indeed, we could show that SPC2996 induced the secretion of MIP-1a and TNF-a into the culture supernatant in a dose-dependent manner, although the responses were weaker than those detected in response to stimulation with the TLR9 agonistic CpG oligonucleotide ODN2216.
Very recently, Spaner et al. 31 reported the results of a phase I/II CLL immunotherapy study where the TLR-7 agonist 852A was found to cause the production of IgM, but not IgG or IgA, by stimulating B cells. Following up on these interesting findings and our functional pathway analysis of the microarray data showing upregulation of genes in the GO category 'Ig production', we serially measured IgM in our patients' serum samples. Again, consistent with the transcriptomic data, we found a significant dose-dependent increase of IgM serum levels in response to SPC2996 treatment, providing further circumstantial evidence that the TLR signaling pathway may play an important role in the biological activity of this ODN. It would be interesting to know whether the increase in IgM was polyclonal (and originated in normal B cells) or monoclonal (and of CLL cell origin), which could be addressed by immunofixation and free light chain analysis of the serum proteins. 31 Although the microarray data in combination with the proteomic serum analysis could readily explain the clinically observed cytokine release syndrome in the study patients, the molecular mechanisms underlying leukemic cell clearance from the blood were more elusive. Although both inflammatory reactions and reduction in lymphocyte counts were found to be dose dependent, we could not observe a stringent statistically significant correlation between the two phenomena, suggesting that the immunostimulatory and antileukemic activity of SPC2996 may be separate effects. Employing clinical multicolor flow cytometry, we examined the effect of therapy with SPC2996 on the distribution of circulating B, T and NK cell subsets over time. When compared with baseline, there were concordant decreases in the percentages of leukemic CD19 þ B along with non-leukemic CD3 þ T and CD3ÀCD56 þ NK cells. To further investigate the molecular pathways involved in this process, we made use of the functional pathway analysis of the SPC2996 response genes. We first speculated that the reduction in circulating lymphocyte numbers may result from downregulation of the SPC2996 target molecule Bcl-2. However, the microarray data did not show a consistent downregulation of Bcl-2 at the mRNA level and this finding was confirmed using a quantitative Bcl-2-specific reverse transcription-PCR assay on the same samples (data not shown). Thus, it appears that the antileukemic activity of SPC2996 cannot solely be explained by an antisense effect, but likely involves activation of pro-apoptotic factors such as BID ( Figure 2 ) and immune stimulation processes.
It has been suggested that induction of leukemic cell death with antisense Bcl-2 inhibition can release tumor antigen that facilitates an effective anti-tumor immune response, which is enhanced by the CpG motif in the antisense Bcl-2 ODN through TLR9. 10, 32 An alternative explanation for the disappearance of the leukemic cells from the circulation following treatment with antisense Bcl-2 ODN may be the upregulation of adhesion and pro-migratory molecules that also emerged in our functional analysis of the microarray data. This process may facilitate the redistribution of CLL cells from the blood stream to peripheral lymphoid tissues, which would also fit the clinical observation of lymph node swelling in response to SPC2996 dosing in some of the patients included in this study. We are currently investigating these different possibilities employing in vitro adhesion assays and a novel in vivo NOD/SCID mouse model of human CLL that was recently established by our group. 33 In view of the pre-clinical studies with SPC2996 showing efficient cellular uptake and subsequent target mRNA downmodulation, 13 the here observed minor effects on Bcl-2 expression in CLL cells were somewhat unexpected. However, very similar results have been obtained with the structurally closely related oblimersen, which also exhibited only modest single-agent activity and no convincing anti-Bcl-2 effect in the initial phase I and II CLL studies. 3, 7 Lack of statistically significant Bcl-2 regulation in response to SPC2996 in this study may be explained at least in part by the small number of patients analyzed. Indeed, SPC2996 induced a moderate downregulation of Bcl-2 in 4/11 patients treated in the 'high-dose group' as compared to 0/7 patients assigned to the 'low-dose cohort' (Figure 2) . However, this effect failed to reach statistical significance.
In summary, we conducted this study to investigate the mechanism of action of SPC2996 and the basis for its inflammatory adverse effects in CLL patients. Combining microarray-based transcriptomic and serum protein analyses, we show that SPC2996 causes a striking activation of the CLL cells and the innate immune system, presumably through activation of the TLR signaling pathway.
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